Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Aug 26, 2019 · 10-Q · 57 days after period end · 0001564590-19-032952
| Metric | Q2 2019 | Q2 2018 |
|---|---|---|
| Net Income | -$13.17M | -$7.85M |
| EPS Diluted | -$9.21 | -$7.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Jun 30, 2019 · filed Aug 26, 2019 · 57 d after period end
